Comparison of side effects with coated lithium carbonate tablets and lithium sulphate preparations giving medium-slow and slow-release.

1977 ◽  
Vol 55 (2) ◽  
pp. 153-158 ◽  
Author(s):  
A. Edström ◽  
G. Persson
Keyword(s):  
Side Effects ◽  
Slow Release ◽  
Lithium Carbonate ◽  
Lithium Sulphate

scholarly journals Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

Gut ◽  
1999 ◽  
Vol 44 (6) ◽  
pp. 886-888 ◽  
Author(s):  
P Deltenre ◽  
A Berson ◽  
P Marcellin ◽  
C Degott ◽  
M Biour ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Adverse Effects ◽  
Liver Dysfunction ◽  
Liver Enzymes ◽  
Slow Release ◽  
Aminosalicylic Acid ◽  
Safe Alternative ◽  
Release Formulation ◽  
Slow Release Formulation

BACKGROUNDTreatment of ulcerative colitis or Crohn’s disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported.CASE REPORTA 65 year old man had increased liver enzymes, anti-nuclear and anti-smooth muscle autoantibodies and IgG levels, and lesions of chronic hepatitis after 21 months of mesalazine treatment. Although liver dysfunction had been identified eight months earlier, simvastatin rather than mesalazine had been withdrawn, without any improvement. In contrast, liver enzyme and IgG levels became normal and autoantibodies disappeared after discontinuation of mesalazine administration.CONCLUSIONContrary to initial expectations, mesalazine can cause most of the sulphasalazine induced adverse effects, and hepatic side effects may be almost as frequent. When liver dysfunction occurs, mesalazine administration should be discontinued to avoid the development of chronic hepatitis and liver fibrosis.

Once-Daily Treatment for Mixed Anxiety/Depressive States: A Comparison of Slow Release Amitriptyline and Fluphenazine with Nortriptyline

1977 ◽  
Vol 5 (2) ◽  
pp. 109-113 ◽  
Author(s):  
R V Magnus ◽  
A A Schiff
Keyword(s):  
Side Effects ◽  
Sustained Release ◽  
Slow Release ◽  
Anxiolytic Effect ◽  
Daily Treatment ◽  
Dry Mouth ◽  
Double Blind ◽  
Once Daily ◽  
Therapeutic Advantage ◽  
Depressive States

Patients suffering from mixed anxiety/depressive states referred to a psychiatric out-patient clinic completed a four week course of either a once-daily tablet of 30 mg nortriptyline with 1· 5 mg fluphenazine, or a sustained release capsule of 50 mg amitriptyline once daily, on a double-blind basis. Depression improved satisfactorily on either treatment, but there was a greater reduction of anxiety on fluphenazine/nortriptyline. Drowsiness, however, occurred more frequently among the patients on amitriptyline, suggesting the sedative properties of this drug did not substitute adequately for a specific anxiolytic effect. Dry mouth was also noticeably more frequent with amitriptyline. As might be expected on pharmacokinetic and physiological grounds, the results suggest that the sustained release characteristics of the amitriptyline preparation lead to a maximization of side-effects during the day without conferring any therapeutic advantage.

scholarly journals Thyrotoxicosis treatment with lithium corbanate. Cases reported

2021 ◽  
Vol 17 (3) ◽  
pp. 22-26
Author(s):  
I. A. Matsueva ◽  
A. B. Dalmatova ◽  
T. V. Andreychenko ◽  
E. N. Grineva
Keyword(s):  
Side Effects ◽  
Thyroid Gland ◽  
Thyroid Hormones ◽  
Toxic Hepatitis ◽  
Lithium Carbonate ◽  
Graves Disease ◽  
Allergic Reactions ◽  
Low Doses ◽  
Short Course ◽  
Toxic Goiter

Treatment of thyrotoxicosis caused by Graves’ disease or multinodular toxic goiter, is not difficult, in most cases, since the prescription of thionamides allows to normalize the level of thyroid hormones quickly and safety. But in a number of cases this therapy might be associated with serious side effects (agranulocytosis, toxic hepatitis, cholestasis), severe allergic reactions and also individual intolerance on thionamides. In such cases lithium carbonate is used, especially in severe thyrotoxic syndrome. It is known, that lithium can accumulate in the thyroid gland at a concentration 3–4 times higher than in the plasma. Perhaps, lithium uses Na+/I- ions. It can inhibit the synthesis and secretion thyroid hormones of thyroid gland. The article presents the cases reported the use of lithium carbonate in thyrotoxicosis treatment before thyroidectomy. Administering low doses of carbonate lithium (900 mg/ per day) renders significant decrease or normalization of thyroid hormones concentration within 7–14 days, thus it let perform thyroidectomy on the patients. No side effects have been identified with such a short course of lithium carbonate treatment.

A Long-term Retrospective Follow-up Study of Patients Treated with Prophylactic Lithium Carbonate

1987 ◽  
Vol 150 (2) ◽  
pp. 175-179 ◽  
Author(s):  
C. Page ◽  
S. Benaim ◽  
F. Lappin
Keyword(s):  
Side Effects ◽  
Complete Remission ◽  
Lithium Carbonate ◽  
Favourable Outcome ◽  
Lithium Level ◽  
Follow Up Study ◽  
High Incidence ◽  
Average Serum

Patients suffering from unipolar and bipolar affective illness, who began treatment with prophylactic lithium carbonate during a 5-year period, were followed up and 59 out of 101 interviewed. Most had been taking lithium for at least 13 years: 49% had a complete remission, 41% a partial but significant response, and 10% no response. No specific individual or illness factor was found to correlate with favourable outcome, and no correlation between average serum lithium level and outcome. No side-effects could be associated specifically with the long-term use of lithium, but there was a surprisingly high incidence of clinical hypothyroidism.

Effect of Assay Methodology on the Prediction of Lithiumc Maintenance Dosage

DICP ◽  
1989 ◽  
Vol 23 (5) ◽  
pp. 372-375 ◽  
Author(s):  
Shyam D. Karki ◽  
Stanley W. Carson ◽  
J.M.C. Holden
Keyword(s):  
Spectrophotometric Method ◽  
Analytical Method ◽  
Slow Release ◽  
Test Dose ◽  
Lithium Carbonate ◽  
Test Methods ◽  
Decimal Place ◽  
Maintenance Dosage ◽  
Clinically Significant ◽  
Bipolar Patients

Test dose methods have been used to predict the maintenance dosage of lithium carbonate tablets in bipolar patients. These methods require a lithium analytical method that is accurate to the second decimal place. Successful use of these test methods has employed the atomic absorption spectrophotometric method, yet many hospitals use a flame spectrophotometric method. We evaluated a two-point method to predict lithium maintenance dosages of slow-release lithium carbonate tablets in 20 bipolar patients using both assay methodologies. No clinically significant differences were found between the two sets of predictions, suggesting that either assay methodology has requisite sensitivity and accuracy for use in test dose predictions of lithium maintenance dosages.

No Effect Of Persantin On Platelet Aggregation And Plasma βTg Levels In Healthy Volunteers

1981 ◽  
Author(s):  
A W A Lensing ◽  
A Sturk ◽  
J W ten Cate
Keyword(s):  
Side Effects ◽  
Healthy Volunteers ◽  
Cerebrovascular Accident ◽  
Slow Release ◽  
Double Blind Study ◽  
Prolonged Administration ◽  
Double Blind ◽  
Normal Limits ◽  
Induced Aggregation ◽  
Release Form

Previous studies from our laboratory revealed no effect of aspirin on plasma βTG levels in healthy volunteers as well as in patients with cerebrovascular accident. This double blind study was undertaken to investigate the effect of prolonged administration of Persantin. Two groups of 10 volunteers each received 4×100 mg Persantin or 2×200 mg daily in slow release form for 21 days. Platelet studies were performed prior to- and once every week during the trial. The volunteers refrained from smoking and were not on oral contraceptives or other drugs. No effect was observed on ADP (1 μ M f.c.) or collagen induced aggregation. All βTG plasma levels were within normal limits i.e. below 60/ml of plasma. No tendency of decreasing levels was observed. Side effects were significantly more observed in the volunteers on slow release Persantin (Mean Whitney Test α < 0.025). Side effects included sensations of a dry mouth and thirst, headache and di2Lzyness.

Patient Preference for Slow Release Potassium Supplements

1975 ◽  
Vol 3 (2) ◽  
pp. 101-103 ◽  
Author(s):  
D M Fraser ◽  
D N S Malone
Keyword(s):  
Side Effects ◽  
Patient Preference ◽  
Slow Release

A comparative, cross-over trial was conducted to determine patient preference for the slow release potassium supplements Slow K and Leo K. Fifty-seven patients took part in the trial and the majority found Leo K preferable to Slow K, principally because Leo K was easier to swallow and caused fewer side-effects. In order to increase the chances of patients following the prescriber's instructions it would seem logical to prescribe Leo K rather than Slow K on the basis of patient preference.

Sign in / Sign up

Export Citation Format

Share Document